Atezolizumab vs Docetaxel in Pretreated Patients with Non-Small Cell Lung Cancer: Final Results From the Randomized Phase II POPLAR and Phase III OAK Clinical Trials.
Identifieur interne : 000552 ( Main/Exploration ); précédent : 000551; suivant : 000553Atezolizumab vs Docetaxel in Pretreated Patients with Non-Small Cell Lung Cancer: Final Results From the Randomized Phase II POPLAR and Phase III OAK Clinical Trials.
Auteurs : Julien Mazieres [France] ; Achim Rittmeyer [Allemagne] ; Shirish Gadgeel [États-Unis] ; Toyoaki Hida [Japon] ; David R. Gandara [États-Unis] ; Diego L. Cortinovis [Italie] ; Fabrice Barlesi ; Wei Yu [États-Unis] ; Christina Matheny [États-Unis] ; Marcus Ballinger [États-Unis] ; Keunchil Park [Corée du Sud]Source :
- Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [ 1556-1380 ] ; 2020.
Abstract
INTRODUCTION
The phase II POPLAR and phase III OAK studies of the anti-PD-L1 immunotherapy atezolizumab in patients with previously treated advanced non-small cell lung cancer (NSCLC) showed significant improvements in survival vs docetaxel. Longer follow-up permits evaluation of continued benefit of atezolizumab. This study reports final overall survival (OS) and safety findings from both trials.
METHODS
POPLAR randomized 287 (atezolizumab,144; docetaxel,143) and OAK randomized 1225 (atezolizumab, 613; docetaxel, 612) patients. Patients received atezolizumab (1200-mg fixed dose) or docetaxel (75 mg/m
RESULTS
A longer OS was observed in patients receiving atezolizumab vs docetaxel in POPLAR (median OS: 12.6 months vs 9.7 months; HR: 0.76 [95% CI: 0.58-1.00]) and OAK (median OS: 13.3 vs 9.8 months; HR: 0.78 [95% CI: 0.68-0.89]. Four-year OS rates in POPLAR were 14.8% (8.7-20.8) and 8.1% (3.2-13.0) for atezolizumab and docetaxel, respectively, and 15.5% (12.4-18.7) and 8.7% (6.2-11.3) in OAK. Atezolizumab had improved OS benefit compared with docetaxel across all PD-L1 expression and histology groups. Most 4-year survivors in the docetaxel arms received subsequent immunotherapy (POPLAR, 50%; OAK, 65%). Of 4-year survivors, most had ECOG PS 0 and nonsquamous histology; approximately half were responders (POPLAR: atezolizumab, 7/15; docetaxel, 3/4; OAK: atezolizumab, 24/43; docetaxel, 11/26). Treatment-related Grade 3/4 adverse events occurred in 27% and 16% of atezolizumab 4-year survivors in POPLAR and OAK, respectively.
CONCLUSIONS
Long-term follow-up suggests a consistent survival benefit with atezolizumab vs docetaxel in patients with previously treated NSCLC regardless of PD-L1 expression, histology, or subsequent immunotherapy. Atezolizumab had no new safety signals, and the safety profile was similar to previous studies.
STUDY IDENTIFIERS
NCT01903993, NCT02008227.
DOI: 10.1016/j.jtho.2020.09.022
PubMed: 33166718
Affiliations:
- Allemagne, Corée du Sud, France, Italie, Japon, États-Unis
- Californie, Michigan, Midi-Pyrénées, Occitanie (région administrative)
- Toulouse
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Atezolizumab vs Docetaxel in Pretreated Patients with Non-Small Cell Lung Cancer: Final Results From the Randomized Phase II POPLAR and Phase III OAK Clinical Trials.</title><author><name sortKey="Mazieres, Julien" sort="Mazieres, Julien" uniqKey="Mazieres J" first="Julien" last="Mazieres">Julien Mazieres</name><affiliation wicri:level="1"><nlm:affiliation>Toulouse University Hospital, Institut Universitaire du Cancer de Toulouse, Université Paul Sabatier, Toulouse, France; Address: Toulouse University Hospital, Larrey Hospital, Chemin de Pouvourville, 314àà Toulouse, France. Electronic address: mazieres.j@chu-toulouse.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Toulouse University Hospital, Institut Universitaire du Cancer de Toulouse, Université Paul Sabatier, Toulouse, France; Address: Toulouse University Hospital, Larrey Hospital, Chemin de Pouvourville, 314àà Toulouse</wicri:regionArea><wicri:noRegion>314àà Toulouse</wicri:noRegion><placeName><settlement type="city">Toulouse</settlement><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region></placeName></affiliation></author><author><name sortKey="Rittmeyer, Achim" sort="Rittmeyer, Achim" uniqKey="Rittmeyer A" first="Achim" last="Rittmeyer">Achim Rittmeyer</name><affiliation wicri:level="1"><nlm:affiliation>Lungenfachklinik Immenhausen, Immenhausen, Germany; Address: Lungenfachklinik, Immenhausen, Robert-Koch-Straße 3, 34376 Immenhausen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Lungenfachklinik Immenhausen, Immenhausen, Germany; Address: Lungenfachklinik, Immenhausen, Robert-Koch-Straße 3, 34376 Immenhausen</wicri:regionArea><wicri:noRegion>34376 Immenhausen</wicri:noRegion><wicri:noRegion>34376 Immenhausen</wicri:noRegion><wicri:noRegion>34376 Immenhausen</wicri:noRegion></affiliation></author><author><name sortKey="Gadgeel, Shirish" sort="Gadgeel, Shirish" uniqKey="Gadgeel S" first="Shirish" last="Gadgeel">Shirish Gadgeel</name><affiliation wicri:level="2"><nlm:affiliation>Henry Ford Cancer Institute/Henry Ford Hospital, Detroit, MI, USA; Address: Henry Ford Cancer Institute/Henry Ford Hospital, Hematology/Oncology-CFP-5, 2799 West Grand Boulevard, Detroit, MI 48202.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Henry Ford Cancer Institute/Henry Ford Hospital, Detroit, MI, USA; Address: Henry Ford Cancer Institute/Henry Ford Hospital, Hematology/Oncology-CFP-5, 2799 West Grand Boulevard, Detroit</wicri:cityArea></affiliation></author><author><name sortKey="Hida, Toyoaki" sort="Hida, Toyoaki" uniqKey="Hida T" first="Toyoaki" last="Hida">Toyoaki Hida</name><affiliation wicri:level="1"><nlm:affiliation>Aichi Cancer Center Hospital, Nagoya, Japan; Address: Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, 464-8681, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Aichi Cancer Center Hospital, Nagoya, Japan; Address: Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, 464-8681</wicri:regionArea><wicri:noRegion>464-8681</wicri:noRegion></affiliation></author><author><name sortKey="Gandara, David R" sort="Gandara, David R" uniqKey="Gandara D" first="David R" last="Gandara">David R. Gandara</name><affiliation wicri:level="2"><nlm:affiliation>UC Davis Comprehensive Cancer Center, Sacramento, CA, USA; Address: UC Davis Comprehensive Cancer Center, 4501 X St, Sacramento, CA 95817.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>UC Davis Comprehensive Cancer Center, Sacramento, CA, USA; Address: UC Davis Comprehensive Cancer Center, 4501 X St, Sacramento</wicri:cityArea></affiliation></author><author><name sortKey="Cortinovis, Diego L" sort="Cortinovis, Diego L" uniqKey="Cortinovis D" first="Diego L" last="Cortinovis">Diego L. Cortinovis</name><affiliation wicri:level="1"><nlm:affiliation>SC Oncologia Medica, SS Lung Unit Asst Ospedale San Gerardo, Monza, Italy; Address: SC Oncologia Medica, VIa Pergolesi 33 Monza, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>SC Oncologia Medica, SS Lung Unit Asst Ospedale San Gerardo, Monza, Italy; Address: SC Oncologia Medica, VIa Pergolesi 33 Monza</wicri:regionArea><wicri:noRegion>VIa Pergolesi 33 Monza</wicri:noRegion></affiliation></author><author><name sortKey="Barlesi, Fabrice" sort="Barlesi, Fabrice" uniqKey="Barlesi F" first="Fabrice" last="Barlesi">Fabrice Barlesi</name><affiliation><nlm:affiliation>Aix-Marseille University, CNRS, INSERM, CRCM, APHM, Marseille, France; Address: Hôpital Nord - Chemin des Bourrelly - 13915 Marseille Cedex 20.</nlm:affiliation><wicri:noCountry code="subField">France; Address: Hôpital Nord - Chemin des Bourrelly - 13915 Marseille Cedex 20</wicri:noCountry></affiliation></author><author><name sortKey="Yu, Wei" sort="Yu, Wei" uniqKey="Yu W" first="Wei" last="Yu">Wei Yu</name><affiliation wicri:level="2"><nlm:affiliation>Genentech, Inc., South San Francisco, CA, USA; Address: Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Genentech, Inc., South San Francisco, CA, USA; Address: Genentech, Inc., 1 DNA Way, South San Francisco</wicri:cityArea></affiliation></author><author><name sortKey="Matheny, Christina" sort="Matheny, Christina" uniqKey="Matheny C" first="Christina" last="Matheny">Christina Matheny</name><affiliation wicri:level="2"><nlm:affiliation>Genentech, Inc., South San Francisco, CA, USA; Address: Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Genentech, Inc., South San Francisco, CA, USA; Address: Genentech, Inc., 1 DNA Way, South San Francisco</wicri:cityArea></affiliation></author><author><name sortKey="Ballinger, Marcus" sort="Ballinger, Marcus" uniqKey="Ballinger M" first="Marcus" last="Ballinger">Marcus Ballinger</name><affiliation wicri:level="2"><nlm:affiliation>Genentech, Inc., South San Francisco, CA, USA; Address: Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Genentech, Inc., South San Francisco, CA, USA; Address: Genentech, Inc., 1 DNA Way, South San Francisco</wicri:cityArea></affiliation></author><author><name sortKey="Park, Keunchil" sort="Park, Keunchil" uniqKey="Park K" first="Keunchil" last="Park">Keunchil Park</name><affiliation wicri:level="1"><nlm:affiliation>Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Address: Samsung Medical Center, 81 Irwon-ro, Gananam-gu, Seoul, 06351, Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Address: Samsung Medical Center, 81 Irwon-ro, Gananam-gu, Seoul, 06351</wicri:regionArea><wicri:noRegion>06351</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:33166718</idno><idno type="pmid">33166718</idno><idno type="doi">10.1016/j.jtho.2020.09.022</idno><idno type="wicri:Area/Main/Corpus">000017</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000017</idno><idno type="wicri:Area/Main/Curation">000017</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000017</idno><idno type="wicri:Area/Main/Exploration">000017</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Atezolizumab vs Docetaxel in Pretreated Patients with Non-Small Cell Lung Cancer: Final Results From the Randomized Phase II POPLAR and Phase III OAK Clinical Trials.</title><author><name sortKey="Mazieres, Julien" sort="Mazieres, Julien" uniqKey="Mazieres J" first="Julien" last="Mazieres">Julien Mazieres</name><affiliation wicri:level="1"><nlm:affiliation>Toulouse University Hospital, Institut Universitaire du Cancer de Toulouse, Université Paul Sabatier, Toulouse, France; Address: Toulouse University Hospital, Larrey Hospital, Chemin de Pouvourville, 314àà Toulouse, France. Electronic address: mazieres.j@chu-toulouse.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Toulouse University Hospital, Institut Universitaire du Cancer de Toulouse, Université Paul Sabatier, Toulouse, France; Address: Toulouse University Hospital, Larrey Hospital, Chemin de Pouvourville, 314àà Toulouse</wicri:regionArea><wicri:noRegion>314àà Toulouse</wicri:noRegion><placeName><settlement type="city">Toulouse</settlement><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region></placeName></affiliation></author><author><name sortKey="Rittmeyer, Achim" sort="Rittmeyer, Achim" uniqKey="Rittmeyer A" first="Achim" last="Rittmeyer">Achim Rittmeyer</name><affiliation wicri:level="1"><nlm:affiliation>Lungenfachklinik Immenhausen, Immenhausen, Germany; Address: Lungenfachklinik, Immenhausen, Robert-Koch-Straße 3, 34376 Immenhausen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Lungenfachklinik Immenhausen, Immenhausen, Germany; Address: Lungenfachklinik, Immenhausen, Robert-Koch-Straße 3, 34376 Immenhausen</wicri:regionArea><wicri:noRegion>34376 Immenhausen</wicri:noRegion><wicri:noRegion>34376 Immenhausen</wicri:noRegion><wicri:noRegion>34376 Immenhausen</wicri:noRegion></affiliation></author><author><name sortKey="Gadgeel, Shirish" sort="Gadgeel, Shirish" uniqKey="Gadgeel S" first="Shirish" last="Gadgeel">Shirish Gadgeel</name><affiliation wicri:level="2"><nlm:affiliation>Henry Ford Cancer Institute/Henry Ford Hospital, Detroit, MI, USA; Address: Henry Ford Cancer Institute/Henry Ford Hospital, Hematology/Oncology-CFP-5, 2799 West Grand Boulevard, Detroit, MI 48202.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Henry Ford Cancer Institute/Henry Ford Hospital, Detroit, MI, USA; Address: Henry Ford Cancer Institute/Henry Ford Hospital, Hematology/Oncology-CFP-5, 2799 West Grand Boulevard, Detroit</wicri:cityArea></affiliation></author><author><name sortKey="Hida, Toyoaki" sort="Hida, Toyoaki" uniqKey="Hida T" first="Toyoaki" last="Hida">Toyoaki Hida</name><affiliation wicri:level="1"><nlm:affiliation>Aichi Cancer Center Hospital, Nagoya, Japan; Address: Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, 464-8681, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Aichi Cancer Center Hospital, Nagoya, Japan; Address: Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, 464-8681</wicri:regionArea><wicri:noRegion>464-8681</wicri:noRegion></affiliation></author><author><name sortKey="Gandara, David R" sort="Gandara, David R" uniqKey="Gandara D" first="David R" last="Gandara">David R. Gandara</name><affiliation wicri:level="2"><nlm:affiliation>UC Davis Comprehensive Cancer Center, Sacramento, CA, USA; Address: UC Davis Comprehensive Cancer Center, 4501 X St, Sacramento, CA 95817.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>UC Davis Comprehensive Cancer Center, Sacramento, CA, USA; Address: UC Davis Comprehensive Cancer Center, 4501 X St, Sacramento</wicri:cityArea></affiliation></author><author><name sortKey="Cortinovis, Diego L" sort="Cortinovis, Diego L" uniqKey="Cortinovis D" first="Diego L" last="Cortinovis">Diego L. Cortinovis</name><affiliation wicri:level="1"><nlm:affiliation>SC Oncologia Medica, SS Lung Unit Asst Ospedale San Gerardo, Monza, Italy; Address: SC Oncologia Medica, VIa Pergolesi 33 Monza, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>SC Oncologia Medica, SS Lung Unit Asst Ospedale San Gerardo, Monza, Italy; Address: SC Oncologia Medica, VIa Pergolesi 33 Monza</wicri:regionArea><wicri:noRegion>VIa Pergolesi 33 Monza</wicri:noRegion></affiliation></author><author><name sortKey="Barlesi, Fabrice" sort="Barlesi, Fabrice" uniqKey="Barlesi F" first="Fabrice" last="Barlesi">Fabrice Barlesi</name><affiliation><nlm:affiliation>Aix-Marseille University, CNRS, INSERM, CRCM, APHM, Marseille, France; Address: Hôpital Nord - Chemin des Bourrelly - 13915 Marseille Cedex 20.</nlm:affiliation><wicri:noCountry code="subField">France; Address: Hôpital Nord - Chemin des Bourrelly - 13915 Marseille Cedex 20</wicri:noCountry></affiliation></author><author><name sortKey="Yu, Wei" sort="Yu, Wei" uniqKey="Yu W" first="Wei" last="Yu">Wei Yu</name><affiliation wicri:level="2"><nlm:affiliation>Genentech, Inc., South San Francisco, CA, USA; Address: Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Genentech, Inc., South San Francisco, CA, USA; Address: Genentech, Inc., 1 DNA Way, South San Francisco</wicri:cityArea></affiliation></author><author><name sortKey="Matheny, Christina" sort="Matheny, Christina" uniqKey="Matheny C" first="Christina" last="Matheny">Christina Matheny</name><affiliation wicri:level="2"><nlm:affiliation>Genentech, Inc., South San Francisco, CA, USA; Address: Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Genentech, Inc., South San Francisco, CA, USA; Address: Genentech, Inc., 1 DNA Way, South San Francisco</wicri:cityArea></affiliation></author><author><name sortKey="Ballinger, Marcus" sort="Ballinger, Marcus" uniqKey="Ballinger M" first="Marcus" last="Ballinger">Marcus Ballinger</name><affiliation wicri:level="2"><nlm:affiliation>Genentech, Inc., South San Francisco, CA, USA; Address: Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Genentech, Inc., South San Francisco, CA, USA; Address: Genentech, Inc., 1 DNA Way, South San Francisco</wicri:cityArea></affiliation></author><author><name sortKey="Park, Keunchil" sort="Park, Keunchil" uniqKey="Park K" first="Keunchil" last="Park">Keunchil Park</name><affiliation wicri:level="1"><nlm:affiliation>Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Address: Samsung Medical Center, 81 Irwon-ro, Gananam-gu, Seoul, 06351, Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Address: Samsung Medical Center, 81 Irwon-ro, Gananam-gu, Seoul, 06351</wicri:regionArea><wicri:noRegion>06351</wicri:noRegion></affiliation></author></analytic><series><title level="j">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</title><idno type="eISSN">1556-1380</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>INTRODUCTION</b></p><p>The phase II POPLAR and phase III OAK studies of the anti-PD-L1 immunotherapy atezolizumab in patients with previously treated advanced non-small cell lung cancer (NSCLC) showed significant improvements in survival vs docetaxel. Longer follow-up permits evaluation of continued benefit of atezolizumab. This study reports final overall survival (OS) and safety findings from both trials.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>POPLAR randomized 287 (atezolizumab,144; docetaxel,143) and OAK randomized 1225 (atezolizumab, 613; docetaxel, 612) patients. Patients received atezolizumab (1200-mg fixed dose) or docetaxel (75 mg/m</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>A longer OS was observed in patients receiving atezolizumab vs docetaxel in POPLAR (median OS: 12.6 months vs 9.7 months; HR: 0.76 [95% CI: 0.58-1.00]) and OAK (median OS: 13.3 vs 9.8 months; HR: 0.78 [95% CI: 0.68-0.89]. Four-year OS rates in POPLAR were 14.8% (8.7-20.8) and 8.1% (3.2-13.0) for atezolizumab and docetaxel, respectively, and 15.5% (12.4-18.7) and 8.7% (6.2-11.3) in OAK. Atezolizumab had improved OS benefit compared with docetaxel across all PD-L1 expression and histology groups. Most 4-year survivors in the docetaxel arms received subsequent immunotherapy (POPLAR, 50%; OAK, 65%). Of 4-year survivors, most had ECOG PS 0 and nonsquamous histology; approximately half were responders (POPLAR: atezolizumab, 7/15; docetaxel, 3/4; OAK: atezolizumab, 24/43; docetaxel, 11/26). Treatment-related Grade 3/4 adverse events occurred in 27% and 16% of atezolizumab 4-year survivors in POPLAR and OAK, respectively.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>Long-term follow-up suggests a consistent survival benefit with atezolizumab vs docetaxel in patients with previously treated NSCLC regardless of PD-L1 expression, histology, or subsequent immunotherapy. Atezolizumab had no new safety signals, and the safety profile was similar to previous studies.</p></div><div type="abstract" xml:lang="en"><p><b>STUDY IDENTIFIERS</b></p><p>NCT01903993, NCT02008227.</p></div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">33166718</PMID><DateRevised><Year>2020</Year><Month>11</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1556-1380</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year><Month>Nov</Month><Day>06</Day></PubDate></JournalIssue><Title>Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</Title><ISOAbbreviation>J Thorac Oncol</ISOAbbreviation></Journal><ArticleTitle>Atezolizumab vs Docetaxel in Pretreated Patients with Non-Small Cell Lung Cancer: Final Results From the Randomized Phase II POPLAR and Phase III OAK Clinical Trials.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S1556-0864(20)30802-9</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jtho.2020.09.022</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The phase II POPLAR and phase III OAK studies of the anti-PD-L1 immunotherapy atezolizumab in patients with previously treated advanced non-small cell lung cancer (NSCLC) showed significant improvements in survival vs docetaxel. Longer follow-up permits evaluation of continued benefit of atezolizumab. This study reports final overall survival (OS) and safety findings from both trials.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">POPLAR randomized 287 (atezolizumab,144; docetaxel,143) and OAK randomized 1225 (atezolizumab, 613; docetaxel, 612) patients. Patients received atezolizumab (1200-mg fixed dose) or docetaxel (75 mg/m<sup>2</sup>) every 3 weeks. Efficacy and safety outcomes were evaluated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A longer OS was observed in patients receiving atezolizumab vs docetaxel in POPLAR (median OS: 12.6 months vs 9.7 months; HR: 0.76 [95% CI: 0.58-1.00]) and OAK (median OS: 13.3 vs 9.8 months; HR: 0.78 [95% CI: 0.68-0.89]. Four-year OS rates in POPLAR were 14.8% (8.7-20.8) and 8.1% (3.2-13.0) for atezolizumab and docetaxel, respectively, and 15.5% (12.4-18.7) and 8.7% (6.2-11.3) in OAK. Atezolizumab had improved OS benefit compared with docetaxel across all PD-L1 expression and histology groups. Most 4-year survivors in the docetaxel arms received subsequent immunotherapy (POPLAR, 50%; OAK, 65%). Of 4-year survivors, most had ECOG PS 0 and nonsquamous histology; approximately half were responders (POPLAR: atezolizumab, 7/15; docetaxel, 3/4; OAK: atezolizumab, 24/43; docetaxel, 11/26). Treatment-related Grade 3/4 adverse events occurred in 27% and 16% of atezolizumab 4-year survivors in POPLAR and OAK, respectively.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Long-term follow-up suggests a consistent survival benefit with atezolizumab vs docetaxel in patients with previously treated NSCLC regardless of PD-L1 expression, histology, or subsequent immunotherapy. Atezolizumab had no new safety signals, and the safety profile was similar to previous studies.</AbstractText><AbstractText Label="STUDY IDENTIFIERS" NlmCategory="UNASSIGNED">NCT01903993, NCT02008227.</AbstractText><CopyrightInformation>Copyright © 2020. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mazieres</LastName><ForeName>Julien</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Toulouse University Hospital, Institut Universitaire du Cancer de Toulouse, Université Paul Sabatier, Toulouse, France; Address: Toulouse University Hospital, Larrey Hospital, Chemin de Pouvourville, 314àà Toulouse, France. Electronic address: mazieres.j@chu-toulouse.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rittmeyer</LastName><ForeName>Achim</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Lungenfachklinik Immenhausen, Immenhausen, Germany; Address: Lungenfachklinik, Immenhausen, Robert-Koch-Straße 3, 34376 Immenhausen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gadgeel</LastName><ForeName>Shirish</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Henry Ford Cancer Institute/Henry Ford Hospital, Detroit, MI, USA; Address: Henry Ford Cancer Institute/Henry Ford Hospital, Hematology/Oncology-CFP-5, 2799 West Grand Boulevard, Detroit, MI 48202.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hida</LastName><ForeName>Toyoaki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Aichi Cancer Center Hospital, Nagoya, Japan; Address: Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, 464-8681, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gandara</LastName><ForeName>David R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>UC Davis Comprehensive Cancer Center, Sacramento, CA, USA; Address: UC Davis Comprehensive Cancer Center, 4501 X St, Sacramento, CA 95817.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cortinovis</LastName><ForeName>Diego L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>SC Oncologia Medica, SS Lung Unit Asst Ospedale San Gerardo, Monza, Italy; Address: SC Oncologia Medica, VIa Pergolesi 33 Monza, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barlesi</LastName><ForeName>Fabrice</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Aix-Marseille University, CNRS, INSERM, CRCM, APHM, Marseille, France; Address: Hôpital Nord - Chemin des Bourrelly - 13915 Marseille Cedex 20.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Genentech, Inc., South San Francisco, CA, USA; Address: Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matheny</LastName><ForeName>Christina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Genentech, Inc., South San Francisco, CA, USA; Address: Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ballinger</LastName><ForeName>Marcus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Genentech, Inc., South San Francisco, CA, USA; Address: Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Keunchil</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Address: Samsung Medical Center, 81 Irwon-ro, Gananam-gu, Seoul, 06351, Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01903993</AccessionNumber><AccessionNumber>NCT02008227</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>11</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Thorac Oncol</MedlineTA><NlmUniqueID>101274235</NlmUniqueID><ISSNLinking>1556-0864</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">atezolizumab</Keyword><Keyword MajorTopicYN="N">docetaxel</Keyword><Keyword MajorTopicYN="N">non-small cell lung cancer</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>07</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>09</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>09</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>9</Day><Hour>20</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>11</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33166718</ArticleId><ArticleId IdType="pii">S1556-0864(20)30802-9</ArticleId><ArticleId IdType="doi">10.1016/j.jtho.2020.09.022</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li><li>Corée du Sud</li><li>France</li><li>Italie</li><li>Japon</li><li>États-Unis</li></country><region><li>Californie</li><li>Michigan</li><li>Midi-Pyrénées</li><li>Occitanie (région administrative)</li></region><settlement><li>Toulouse</li></settlement></list><tree><noCountry><name sortKey="Barlesi, Fabrice" sort="Barlesi, Fabrice" uniqKey="Barlesi F" first="Fabrice" last="Barlesi">Fabrice Barlesi</name></noCountry><country name="France"><region name="Occitanie (région administrative)"><name sortKey="Mazieres, Julien" sort="Mazieres, Julien" uniqKey="Mazieres J" first="Julien" last="Mazieres">Julien Mazieres</name></region></country><country name="Allemagne"><noRegion><name sortKey="Rittmeyer, Achim" sort="Rittmeyer, Achim" uniqKey="Rittmeyer A" first="Achim" last="Rittmeyer">Achim Rittmeyer</name></noRegion></country><country name="États-Unis"><region name="Michigan"><name sortKey="Gadgeel, Shirish" sort="Gadgeel, Shirish" uniqKey="Gadgeel S" first="Shirish" last="Gadgeel">Shirish Gadgeel</name></region><name sortKey="Ballinger, Marcus" sort="Ballinger, Marcus" uniqKey="Ballinger M" first="Marcus" last="Ballinger">Marcus Ballinger</name><name sortKey="Gandara, David R" sort="Gandara, David R" uniqKey="Gandara D" first="David R" last="Gandara">David R. Gandara</name><name sortKey="Matheny, Christina" sort="Matheny, Christina" uniqKey="Matheny C" first="Christina" last="Matheny">Christina Matheny</name><name sortKey="Yu, Wei" sort="Yu, Wei" uniqKey="Yu W" first="Wei" last="Yu">Wei Yu</name></country><country name="Japon"><noRegion><name sortKey="Hida, Toyoaki" sort="Hida, Toyoaki" uniqKey="Hida T" first="Toyoaki" last="Hida">Toyoaki Hida</name></noRegion></country><country name="Italie"><noRegion><name sortKey="Cortinovis, Diego L" sort="Cortinovis, Diego L" uniqKey="Cortinovis D" first="Diego L" last="Cortinovis">Diego L. Cortinovis</name></noRegion></country><country name="Corée du Sud"><noRegion><name sortKey="Park, Keunchil" sort="Park, Keunchil" uniqKey="Park K" first="Keunchil" last="Park">Keunchil Park</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/PoplarV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000552 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000552 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= PoplarV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:33166718
|texte= Atezolizumab vs Docetaxel in Pretreated Patients with Non-Small Cell Lung Cancer: Final Results From the Randomized Phase II POPLAR and Phase III OAK Clinical Trials.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:33166718" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a PoplarV1
| This area was generated with Dilib version V0.6.37. |  |